RxDoctor Payments Data

Yaseen Hashish, MD

Nephrology · Flint, MINPI 1821176785

Payments from drug & device makers

$534in general payments, 2019–2025

Across 17 payments — averaging $31.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$240
  • Fresenius USA Marketing, Inc.$124
  • Otsuka America Pharmaceutical, Inc.$51
  • Amgen$44
  • Akebia Therapeutics Inc$23
  • Novo Nordisk$20
  • plus $31 from 2 others

What the payments were for

  • Food & beverage$50394%
  • Education$316%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$534 in reported general payments places this provider in the 40th percentile of 325 nephrology providers in Michigan.

See all nephrology providers in Michigan

Medicare billing

Part B allowed, 2024
$294,245
Medicare patients
525
Services billed
2,063

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol212$172,976
AuryxiaFerric Citrate44$112,318
JardianceEmpagliflozin94$107,502
VelphoroSucroferric Oxyhydroxide19$47,339
RayaldeeCalcifediol37$45,165
InvokanaCanagliflozin17$23,330
LokelmaSodium Zirconium Cyclosilicate33$21,794
Lanthanum Carbonate13$18,756
KerendiaFinerenone19$15,649
OzempicSemaglutide16$14,819
Sevelamer Carbonate60$13,031
XareltoRivaroxaban21$11,500
Cinacalcet Hcl15$6,602
Nifedipine ErNifedipine198$5,870
DapagliflozinDapagliflozin Propanediol11$4,620

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Lokelma$240$194,770245 claims
Akebia Therapeutics IncAuryxia$23$112,31844 claims
Fresenius USA Marketing, Inc.Velphoro$124$47,33919 claims
OPKO Pharmaceuticals, LLCRayaldee$15$45,16537 claims
Novo NordiskOzempic$20$14,81916 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 325 nephrology providers in Michigan.

Other nephrology in Flint

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →